Remedy succeeds in listing on KOSDAQ after two failed attempts

Remedy, after failing to clear the listing threshold twice, is being listed on KOSDAQ after its third attempt. The news was reported as 7in the third week of the month (13∼17) as one of the major stories in the initial public offering market.

The company had previously gone through the listing process twice, but in the end did not reach a listing. This listing is the result of the company resuming the public offering process and finally meeting the requirements for listing on the securities market.

Detailed items in the listing process, such as the public offering schedule, offering price and underwriters, follow the information disclosed by the company. Investors should check the disclosed documents for the allocation to investors and the general subscription schedule.

This listing may affect investor demand for the public offering and trading flow on the first day of listing. The allocation of shares in the offering and the number of shares available for circulation are important variables in investment decisions.

Remedi’s listing drew attention in the IPO market as it coincided with other public offerings taking place during the same period. The success of the offering and institutional demand forecasts may determine future share-price volatility.

If additional disclosures related to the company are released, investors should first check key information such as the offering price, subscription schedule, and listing date. Related disclosures can be confirmed through the Financial Supervisory Service’s electronic disclosure system and exchange disclosures.